Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research

PLoS Medicine

Volumn 10, Issue 2, 2013, Pages

  Riley, Richard D ^a   Hayden, Jill A ^b   Steyerberg, Ewout W ^c   Moons, Karel G M ^d   Abrams, Keith ^e   Kyzas, Panayiotis A ^f   Malats, Núria ^g   Briggs, Andrew ^h   Schroter, Sara ⁱ   Altman, Douglas G ^j   Hemingway, Harry ^k  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b DALHOUSIE UNIVERSITY   (Canada)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

^f NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^g Centro Nacional de Investigaciones Oncológicas   (Spain)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ BMJ   (United Kingdom)

^j UNIVERSITY OF OXFORD   (United Kingdom)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; HOMOCYSTEINE; PROTEIN P53; TAMOXIFEN;

ACUTE HEART INFARCTION; ARTICLE; BLADDER CANCER; BONE INJURY; BREAST CANCER; CLINICAL PRACTICE; CLINICAL RESEARCH; CORONARY ARTERY DISEASE; DISEASE COURSE; HEALTH CARE QUALITY; HUMAN; INTERVENTION STUDY; LOW BACK PAIN; LUNG NON SMALL CELL CANCER; META ANALYSIS (TOPIC); OSTEOSARCOMA; OUTCOME ASSESSMENT; PATIENT CARE; PROGNOSIS; PROGNOSTIC FACTOR RESEARCH; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPLICATION STUDY; TRAUMATIC BRAIN INJURY; TREATMENT RESPONSE; ULCER PERFORATION; WHIPLASH INJURY; DECISION SUPPORT SYSTEM; HEALTH SERVICES RESEARCH; MEDICAL RESEARCH; METHODOLOGY; PREDICTIVE VALUE; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; HEALTH SERVICES RESEARCH; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84874455583     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001380     Document Type: Article

References (68)

1. Schumacher M, Bastert G, Bojar H, Hubner K, Olschewski M, et al. (1994) Randomized 2×2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group. J Clin Oncol 12: 2086-2093.
2. Hemingway H, Croft P, Perel P, Hayden JA, Abrams K, Timmis A, et al. (2013) Prognosis research strategy (PROGRESS) 1: A framework for researching clinical outcomes. BMJ 346: e5595.
3. Riley RD, Sauerbrei W, Altman DG, (2009) Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer 100: 1219-1229.
4. Azzato EM, Tyrer J, Fasching PA, Beckmann MW, Ekici AB, et al. (2010) Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. J Natl Cancer Inst 102: 650-662.
5. Mostertz W, Stevenson M, Acharya C, Chan I, Walters K, et al. (2010) Age- and sex-specific genomic profiles in non-small cell lung cancer. JAMA 303: 535-543.
6. Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, et al. (2004) A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 10: 4-12.
7. Chou R, Shekelle P, (2010) Will this patient develop persistent disabling low back pain? JAMA 303: 1295-1302.
8. National Institute for Health and Clinical Excellence (2008) NICE technology appraisal guidance 152: drug-eluting stents for the treatment of coronary artery disease (part review of NICE technology appraisal guidance 71). NICE.
9. Altman DG, Riley RD, (2005) An evidence-based approach to prognostic markers. Nature Clin Pract Oncol 2: 466-472.
10. Rifai N, Altman DG, Bossuyt PM, (2008) Reporting bias in diagnostic and prognostic studies: time for action. Clin Chem 54: 1101-1103.
11. Simon R (2001) Evaluating prognostic factor studies. In: Gospodarowicz MKea, editor. Prognostic factors in cancer. Wiley-Liss. pp. 49-56.
12. Sauerbrei W (2005) Prognostic factors-confusion caused by bad quality of design, analysis and reporting of many studies. In: Bier H, editor. Current research in head and neck cancer. Advances in otorhinolaryngology. Karger. pp. 184-200.
13. Von Korff M, Miglioretti DL, (2005) A prognostic approach to defining chronic pain. Pain 117: 304-313.
14. Subramanian J, Simon R, (2010) Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 102: 464-474.
15. De Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, et al. (2009) Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 361: 653-663.
16. Steyerberg EW, Mushkudiani N, Perel P, Butcher I, Lu J, et al. (2008) Predicting outcome after traumatic brain injury: Development and international validation of prognostic scores based on admission characteristics. PLoS Med 5: e165 doi:10.1371/journal.pmed.0050165.
17. Steyerberg EW, Moons KGM, van der Windt DA, Hayden JA, Perel P, et al. (2013) Prognosis research strategy (PROGRESS) 3: prognostic model research. PLoS Med 10: e1001381 doi:10.1371/journal.pmed.1001381.
18. Trusheim MR, Berndt ER, Douglas FL, (2007) Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 6: 287-293.
19. National Institute for Clinical Excellence (2010) NICE technology appraisal guidance 192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer. NICE.
20. Clark GM, (2008) Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib. Mol Oncol 1: 406-412.
21. Hingorani A, van der Windt DA, Riley RD, Abrams K, Moons KGM, Steyerberg EW, et al. (2013) Prognosis research strategy (PROGRESS) 4: stratified medicine research. BMJ 346: e5793.
22. Lassere MN, Johnson KR, Boers M, Tugwell P, Brooks P, et al. (2007) Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol 34: 607-615.
23. Moons KG, (2010) Criteria for scientific evaluation of novel markers: a perspective. Clin Chem 56: 537-541.
24. Executive summary: standards of medical care in diabetes-2011 (2011) Diabetes Care. (suppl 1): pp. S4-10.
25. Renehan AG, Egger M, Saunders MP, O'Dwyer ST, (2002) Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 324: 813.
26. Pincus T, Vogel S, Burton AK, Santos R, Field AP, (2006) Fear avoidance and prognosis in back pain. Arthritis Rheum 54: 3999-4010.
27. Iles RA, Davidson M, Taylor NF, (2008) Psychosocial predictors of failure to return to work in non-chronic non-specific low back pain: a systematic review. Occup Environ Med 65: 507-517.
28. Picavet HS, Vlaeyen JW, Schouten JS, (2002) Pain catastrophizing and kinesiophobia: predictors of chronic low back pain. Am J Epidemiol 156: 1028-1034.
29. Fritz JM, George SZ, Delitto A, (2001) The role of fear-avoidance beliefs in acute low back pain: relationships with current and future disability and work status. Pain 94: 7-15.
30. Von Korff M, Balderson BH, Saunders K, Miglioretti DL, Lin EH, et al. (2005) A trial of an activating intervention for chronic back pain in primary care and physical therapy settings. Pain 113: 323-330.
31. Shah AD, Nicholas O, Timmis AD, Feder G, Abrams KR, et al. (2011) Threshold haemoglobin levels and the prognosis of stable coronary disease: two new cohorts and a systematic review and meta-analysis. PLoS Med 8: e1000439 doi:10.1371/journal.pmed.1000439.
32. Marmarou A, Lu J, Butcher I, McHugh GS, Mushkudiani NA, et al. (2007) IMPACT database of traumatic brain injury: design and description. J Neurotrauma 24: 239-250.
33. Van Beek JGM, Mushkudiani NA, Steyerberg EW, Butcher I, McHugh GS, et al. (2007) Prognostic value of admission laboratory parameters in traumatic brain injury: results from the IMPACT study. J Neurotrauma 24: 315-328.
34. Hayden JA, Côté P, Steenstra IA, Bombardier C, (2008) QUIPS-LBP Working Group (2008) Identifying phases of investigation helps planning, appraising, and applying the results of explanatory prognosis studies. J Clin Epidemiol 61: 552-560.
35. Wald DS, Wald NJ, Morris JK, Law M, (2006) Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ 333: 1114-1117.
36. Maas AI, Marmarou A, Murray GD, Teasdale SG, Steyerberg EW, (2007) Prognosis and clinical trial design in traumatic brain injury: the IMPACT study. J Neurotrauma 24: 232-238.
37. Royston P, Altman DG, Sauerbrei W, (2006) Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 25: 127-141.
38. Hernandez AV, Eijkemans MJ, Steyerberg EW, (2006) Randomized controlled trials with time-to-event outcomes: how much does prespecified covariate adjustment increase power? Ann Epidemiol 16: 41-48.
39. Maas AI, Steyerberg EW, Marmarou A, McHugh GS, Lingsma HF, et al. (2010) IMPACT recommendations for improving the design and analysis of clinical trials in moderate to severe traumatic brain injury. Neurotherapeutics 7: 127-134.
40. Roozenbeek B, Maas AI, Lingsma HF, Butcher I, Lu J, et al. (2009) Baseline characteristics and statistical power in randomized controlled trials: selection, prognostic targeting, or covariate adjustment? Crit Care Med 37: 2683-2690.
41. Altman DG, Lyman GH, (1998) Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 52: 289-303.
42. Dupuy A, Simon RM, (2007) Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 99: 147-157.
43. Tinker AV, Boussioutas A, Bowtell DD, (2006) The challenges of gene expression microarrays for the study of human cancer. Cancer Cell 9: 333-339.
44. Holländer N, Sauerbrei W (2006) On statistical approaches for the multivariable analysis of prognostic factor studies. In: Auget J-L, Balakrishnan N, Mesbah M, Molenberghs G, editors. Advances in statistical methods for the health sciences. Birkhäuser. pp. 19-38.
45. Simon R, Altman DG, (1994) Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69: 979-985.
46. Hemingway H, Riley RD, Altman DG, (2009) Ten steps towards improving prognosis research. BMJ 339: b4184.
47. Schumacher M, Holländer N, Schwarzer G, Sauerbrei W (2006) Prognostic factor studies. In: Crowley J, Ankerst DP, editors. Handbook of statistics in clinical oncology. 2nd ed. Chapman & Hall/CRC Press. pp. 289-333.
48. Altman DG, Lausen B, Sauerbrei W, Schumacher M, (1994) Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86: 829-835.
49. Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, et al. (2003) Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer 88: 1191-1198.
50. Kyzas PA, Loizou KT, Ioannidis JP, (2005) Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 97: 1043-1055.
51. Riley RD, Burchill SA, Abrams KR, Heney D, Lambert PC, et al. (2003) A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma. Health Technol Assess 7: 1-162.
52. Kyzas PA, Denaxa-Kyza D, Ioannidis JP, (2007) Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 43: 2559-2579.
53. Altman DG, (2001) Systematic reviews of evaluations of prognostic variables. BMJ 323: 224-228.
54. Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, et al. (2005) P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6: 678-686.
55. Hemingway H, Philipson P, Chen R, Fitzpatrick NK, Damant J, et al. (2010) Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med 7: e1000286 doi:10.1371/journal.pmed.1000286.
56. Clay FJ, Newstead SV, McClure RJ, (2010) A systematic review of early prognostic factors for return to work following acute orthopaedic trauma. Injury 41: 787-803.
57. Kamper SJ, Rebbeck TJ, Maher CG, McAuley JH, Sterling M, (2008) Course and prognostic factors of whiplash: a systematic review and meta-analysis. Pain 138: 617-629.
58. Bramer JA, van Linge JH, Grimer RJ, Scholten RJ, (2009) Prognostic factors in localized extremity osteosarcoma: a systematic review. Eur J Surg Oncol 35: 1030-1036.
59. Moller MH, Adamsen S, Thomsen RW, Moller AM, (2010) Preoperative prognostic factors for mortality in peptic ulcer perforation: a systematic review. Scand J Gastroenterol 45: 785-805.
60. Hayden JA, Chou R, Hogg-Johnson S, Bombardier C, (2009) Systematic reviews of low back pain prognosis had variable methods and results: guidance for future prognosis reviews. J Clin Epidemiol 62: 781-796.
61. Hayden JA, Cote P, Bombardier C, (2006) Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144: 427-437.
62. Riley RD, Ridley G, Williams K, Altman DG, Hayden J, et al. (2007) Prognosis research: toward evidence-based results and a Cochrane methods group. J Clin Epidemiol 60: 863-865 author reply 865-866.
63. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93: 387-391.
64. Riley RD, Lambert PC, Abo-Zaid G, (2010) Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 340: c221.
65. Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C, (1999) Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol 28: 1-9.
66. Abo-Zaid G, Sauerbrei W, Riley RD, (2012) Individual participant data meta-analysis of prognostic factor studies: state of the art? BMC Med Res Methodol 12: 56.
67. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, et al. (2009) Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circ Cardiovasc Qual Outcomes 119: 2408-2416.
68. Moons KG, (2010) Criteria for scientific evaluation of novel markers: a perspective. Clin Chem 56: 537-541.